Drug Augmentation for Treatment-refractory Major Depressive Disorder

難治型重度憂鬱症之藥物強化治療

陳奕安(Cynthia Yi-An Chen)；邱一航(Yi-Hang Chiu)；沈武典(Winston W. Shen)

a second antidepressant ； second generation antipsychotic drugs ； lithium ； thyroid hormone ； 第二種抗憂鬱劑 ； 第二代抗精神病劑 ； 鋰鹽 ； 甲狀腺賀爾蒙

台灣精神醫學

32卷3期（2018 / 09 / 01）

188 - 199+ii

英文

Major depressive disorder (MDD) is one of the most frequent psychiatric diseases seen in the clinic. Most MDD patients can be treated reliably and comfortably with the use of one antidepressant. But some patients have treatment-refractory depression (TRD), which needs to be managed with switch of the antidepressant or augmentation therapy with another antidepressant or other drugs. Therefore, managing TRD is a challenge for practicing psychiatrists. In this overview, the authors are focusing on treating TRD with augmentation therapy. First, clinicians need to be well-versed in behavioral and physiological classification of antidepressants as a logical basis of choosing an appropriate antidepressant for add-on therapy. Second, clinicians need to be familiarized with data of clinical drug trials for treating TRD with second-generation antipsychotic drugs such as aripiprazole, olanzapine, and quetiapine, approved by the Food and Drug Administration (FDA) of the United States. Third, clinicians need to recognize the use of lithium and thyroid hormone as an add-on drugs for treating patients with TRD. Finally, the patients need to be educated to adapt a healthy lifestyle such as having the habit of regular aerobic exercise, refraining from substance uses, etc. With all those tips, the authors believe that the goal of remission can be more easily achieved for patients with TRD.

重度憂鬱症為門診最常見的精神科疾病之一。大多數的重度憂鬱症病人能藉由單一種抗憂鬱劑得到可靠並有效的治療。但有些病人屬於難治型憂鬱症，則需要接受藥物的轉換、合併另一種抗憂鬱劑或其他藥物的強化治療。因此，如何治療難治型憂鬱症的病人對於精神科醫師來說是一大挑戰。在本篇文章裡，作者主要聚焦在以強化治療的策略來治療難治型憂鬱症。首先，臨床醫師需要充分精通抗憂鬱劑的行為生理機轉分類，以作為選擇合適的抗憂鬱劑作為輔助治療的邏輯基礎。其次，臨床醫師應熟悉美國食品藥品監督管理局核准能作為難治型憂鬱症治療用藥，包括aripiprazole，olanzapine以及quetiapine等第二代抗精神病劑之臨床藥物研究。第三，臨床醫師應理解使用鋰鹽，做為治療難治型憂鬱症的輔助用藥。第四，甲狀腺賀爾蒙的收使用，做為治療難治型憂鬱症的輔助用藥。最後，病人必須被衛教以調整達到健康的生活方式，如養成規律的有氧運動習慣，戒除不當的物質使用等。藉由以上訣竅，作者相信難治型憂鬱症病人應能更容易達到緩解的目標。

1. Dunner, DL(2013).Treatment-resistant depression.Taiwanese Journal of Psychiatry,27,110-120.
   連結：
2. Warren, CR,Serrato, JJ,Maguire, GA(2012).Off-lebel uses of second-generation antipsychotic drugs.Taiwanese Journal of Psychiatry,26,162-176.
   連結：
3. Agid, O,Lerer, B(2003).Algorithm-based treatment of major depression in an outpatient clinic: clinical correlates of response to a specific serotonin reuptake inhibitor and to triiodothyronine augmentation.Int J Neuropsychopharmacol,6,41-49.
4. American Psychiatric Association(2010).Practice Guideline for the Treatment of Patients with Major Depressive Disorder, Third Edition.Washington DC:American Psychiatric Association.
5. American Psychiatric Association(2013).Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5).Washington DC:American Psychiatric Association.
6. Berman, RM,Fava, M,Thase, ME(2009).Aripiprazole augmentation in major depressive disorder: a doubleblind, placebo-controlled study in patients with inadequate response to antidepressants.CNS Spectr,14,197-206.
7. Berman, RM,Marcus, RN,Swanink, R(2007).The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study.J Clin Psychiatry,68,843-853.
8. Brecht, S,Desaiah, D,Elisete, S,Marechal, ES(2011).Efficacy and safety of duloxetine 60 mg and 120 mg daily in patients hospitalized for severe depression: a double-blind randomized trial.J Clin Psychiatry,72,1086-1109.
9. Bschor, T,Lewitzka, U,Sasse, J,Adli, M,Köberle, U,Bauer, M(2003).Lithium augmentation in treatment-resistant depression: clinical evidence, serotonergic and endocrine mechanisms.Pharmacopsychiatry,36(suppl 3),S230-S234.
10. Chiu, YH,Lee, TH,Shen, WW(2007).Use of low-dose topiramate in substance use disorder and body weight control.Psychiatry Clin Sci,61,630-633.
11. Cooper-Kazaz, R,Lerer, B(2008).Efficacy and safety of triiodothyronine supplementation in patients with major depressive disorder treated with specific serotonin reuptake inhibitors.Int J Neuropsychopharmacol,11,685-699.
12. Corya, SA,Williamson, D,Sanger, TM,Briggs, SD,Case, M,Tollefson, G(2006).A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression.Depress Anxiety,23,364-372.
13. Dorée, JP,Des Rosiers, J,Lew, V(2007).Quetiapine augmentation of treatment-resistant depression: a comparison with lithium.Curr Med Res Opin,23,333-341.
14. Dunner, DL,Rush, AJ,Russell, JM,Woodward, S,Wingard, P,Allen, J(2006).Prospective, long-term, multicenter study of the naturalistic outcomes of patients with treatment-resistant depression.J Clin Psychiatry,67,688-695.
15. Eison, AS(1990).Azapirones: history of development.J Clin Psychopharmacol,10(3 Suppl),2S-5S.
16. El-Khalili, N,Joyce, M,Atkinson, S(2010).Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study.Int J Neuro-psychopharmacol,13,917-932.
17. Hartberg, J,Garrett-Walcott, S,De Gioannis, A(2018).Impact of oral ketamine augmentation on hospital admissions in treatment-resistant depression and PTSD: a retrospective study.Psychopharmacology,235,393-398.
18. Healy, D,McMonagle, T(1997).The enhancement of social functioning as a therapeutic principle in the management of depression.J Psychopharmacol,11(supp 4),S25-S31.
19. Keller, MB,Klerman, GL,Lavori, PW(1984).Longterm outcome of episodes of major depression: clinical and public health significance.JAMA,252,788-792.
20. Kessler, RC,Berglund, P,Demler, O(2003).The epidemiology of major depressive disorder results from the National Comorbidity Survey Replication (NCS-R).JAMA,289,3095-3105.
21. Koponen, H,Allgulander, C,Erickson, J(2007).Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary care physicians.Prim Care Companion J Clin Psychiatry,9,100-107.
22. Lopez-Ibor, J,Guelfi, JD,Pletan, Y,Tournoux, A,Prost, JF(1996).Milnacipran and selective serotonin reuptake inhibitors in major depression.Int Clin Psychopharmacol,11(Suppl 4),S41-S46.
23. López-Muñoz, F,Shen, WW,Pilar D’Ocon, P,Romero, A,Álamo, C(2018).A history of the pharmacological treatment of bipolar disorder.Int J Mol Sci,19,2143.
24. Marcus, RN,McQuade, RD,Carson, WH(2008).The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multi+center, randomized, double-blind, placebo-controlled study.J Clin Psychopharmacol,28,156-165.
25. McGrath, PJ,Stewart, JW,Fava, M(2006).Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report.Am J Psychiatry,163,1531-1541.
26. Mojtabai, R(2017).Nonremission and time to remission among remitters in major depressive disorder: revisiting STAR*D.Depress Anxiety,34,1123-1133.
27. Nelson, JC,Andrei Pikalov, A,Berman, RM(2008).Augmentation treatment in major depressive disorder: focus on aripiprazole.Neuropsychiatr Dis Treat,4,937-948.
28. Nelson, JC,Papakostas, GI(2009).Atypical antipsychotic augmentation in major depressive disorder: a metaanalysis of placebo-controlled randomized trials.Am J Psychiatry,166,980-991.
29. Nierenberg, AA,Fava, M,Trivedi, MH(2006).A comparison of lithium and T3 augmentation following two failed medication treatments for depression: a STAR*D report.Am J Psychiatry,163,1519-1530.
30. Nierenberg, AA,Keefe, BR,Leslie, VC(1999).Residual symptoms in depressed patients who respond acutely to fluoxetine.J Clin Psychiatry,60,221-225.
31. Price, LH,Charney, DS,Heninger, GR(1986).Variability of response to lithium augmentation in refractory depression.Am J Psychiatry,143,1387-1392.
32. Rush, AJ,Trivedi, MH,Wisniewski, SR(2006).Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.Am J Psychiatry,163,1905-1917.
33. Shelton, RC,Tollefson, GD,Tohen, M(2001).A novel augmentation strategy for treating resistant major depression.Am J Psychiatry,158,131-134.
34. Shen, WW(2018).Anticraving therapy for alcohol use disorder: a clinical review.Neuropsychopharmacol Rep,38,105-116.
35. Shen, WW(2016).Antidepressant therapy.Aino Journal,15,1-13.
36. Shen, WW(2011).Clinical Psychopharmacology for the 21st Century, The Third Edition.Taipei:Ho-Chi Publishing Company.
37. Shiroma, PR,Johns, B,Kuskowski, M(2014).Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression.J Affect Disord,155,123-129.
38. Sinyor, M,Schaffer, A,Levitt, A(2010).The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Trial: a review.Can J Psychiatry,55,126-135.
39. Stahl, SM(2014).Mechanism of action of agomelatine: a novel antidepressant exploiting synergy between monoaminergic and melatonergic properties.CNS Spectr,19,207-212.
40. Sugawara, H,Sakamoto, K,Harada, T,Ishigooka, J(2010).Predictors of efficacy in lithium augmentation for treatment-resistant depression.J Affect Disord,125,165-168.
41. Thase, ME,Entsuah, AR,Rudolph, RL(2001).Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors.Br J Psychiatry,178,234-241.
42. Thase, ME,Nierenberg, AA,Vrijland, P,van Oers, HJ,Schutte, AJ,Simmons, JH(2010).Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression.Int Clin Psychopharmacol,25,189-198.
43. Thase, ME,Pritchett, YL,Ossanna, MJ,Swindle, RW,Xu, J,Detke, MJ(2007).Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder.J Clin Psychopharmacol,27,672-676.
44. Zimmerman, M,McGlinchey, JB,Posternak, MA,Friedman, M,Attiullah, N,Boerescu, D(2006).How should remission from depression be defined? the depressed patient's perspective.Am J Psychiatry,163,148-150.

1. Pan, Yi-Ju(2019).Unmet Needs for the Management of Depression.臺灣精神醫學,33(3),122-124.
2. Shen, Winston W.,Chang, Shen Chieh(2019).Antidepressant Therapy in Patients with Cancer: A Clinical Review.臺灣精神醫學,33(1),13-19.
3. (2019)。陷落與攀升：一位畫家憂鬱症狀的發展脈絡與療癒歷程之研究。東臺灣特殊教育學報，21，105-124。